Who makes SYS6010 jnjection?

SYS6010 jnjection is developed by CSPC Megalith Biopharmaceutical Co.,Ltd..

What development phase is SYS6010 jnjection in?

SYS6010 jnjection is in Phase 1.

Last reviewed 2026-04-19 · How we verify

SYS6010 jnjection

CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase 1 active Small molecule

At a glance

Generic name	SYS6010 jnjection
Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYS6010 jnjection CI brief — competitive landscape report
SYS6010 jnjection updates RSS · CI watch RSS
CSPC Megalith Biopharmaceutical Co.,Ltd. portfolio CI